Therapeutic Vaccine Market Size, Share & Trends Analysis Report by Product (Autoimmune Disease Vaccines, Neurological Disease Vaccines, Cancer Vaccines, Infectious Disease Vaccines and Others), By Technology (Allogeneic Vaccine and Autologous Vaccine), and Forecast 2020-2026
The global therapeutic vaccine market is anticipated to grow significantly during the forecast period. Therapeutics vaccine are generally used after the infection or disease has curbed the body. The major factor contributing to the growth of the market include increasing R&D activity related to therapeutic vaccine to broadening the scope of vaccine is, which in turn, driving the global therapeutic vaccine market.
The therapeutic vaccine market is segmented on the basis of the product and technology. Based on the product, the market is sub-segmented into autoimmune disease vaccines, neurological disease vaccines, cancer vaccines, infectious disease vaccines, and others. Autoimmune disease vaccines is expected to hold significant market share. Further, based on the technology, the market is bifurcated into the allogeneic vaccine and autologous vaccine.
Geographically, the study of the global therapeutic vaccine market report covers the analysis of four major regions including North America (the US and Canada), Europe (UK, Germany, Italy, Spain, France, and Rest of Europe), Asia-Pacific (China, Japan, India, and the Rest of Asia-Pacific), and the Rest of the World. Asia-Pacific is estimated to exhibit a significant growth rate in the global therapeutic vaccine market during the forecast period. The improving healthcare infrastructure further gives a boost to the regional growth of the market. North America is expected to hold significant share in the market. The growth in the region is due to the well-developed healthcare and R&D sector that caters the requirement of new and advanced therapeutic vaccines.
Moreover, the study of the global therapeutic vaccine market report covers the analysis of various players operating in the market. Some of the key players covered in the report include Agenus Inc., GlaxoSmithKline plc, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sanofi SA, Eli Lilly and Co., and others. The market players are considerably contributing to the market growth by adopting various strategies including merger, and acquisition, collaborations with government, funding, and various advancements in the R&D to stay competitive in the market. For instance, in February 2019, Merck & Co. Inc. acquired Immune Design and its cancer vaccines platform in a deal of total $300 million.
Research Methodology
The market study of the global therapeutic vaccine market is incorporated by extensive primary and secondary research. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.
In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.
Secondary Sources Include:
The report is intended for the pharmaceutical industry, drug manufacturers, vaccine manufacturers, hospitals & clinics, government organizations, regulatory bodies, and other market participants for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, market determinants, and future market growth. The report will serve as a source for a 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.
Market Segmentation:
1. Global Therapeutic Vaccine Market Research and Analysis by Product
2. Global Therapeutic Vaccine Market Research and Analysis by Technology
The Report Covers
The global therapeutic vaccine market is anticipated to grow significantly during the forecast period. Therapeutics vaccine are generally used after the infection or disease has curbed the body. The major factor contributing to the growth of the market include increasing R&D activity related to therapeutic vaccine to broadening the scope of vaccine is, which in turn, driving the global therapeutic vaccine market.
The therapeutic vaccine market is segmented on the basis of the product and technology. Based on the product, the market is sub-segmented into autoimmune disease vaccines, neurological disease vaccines, cancer vaccines, infectious disease vaccines, and others. Autoimmune disease vaccines is expected to hold significant market share. Further, based on the technology, the market is bifurcated into the allogeneic vaccine and autologous vaccine.
Geographically, the study of the global therapeutic vaccine market report covers the analysis of four major regions including North America (the US and Canada), Europe (UK, Germany, Italy, Spain, France, and Rest of Europe), Asia-Pacific (China, Japan, India, and the Rest of Asia-Pacific), and the Rest of the World. Asia-Pacific is estimated to exhibit a significant growth rate in the global therapeutic vaccine market during the forecast period. The improving healthcare infrastructure further gives a boost to the regional growth of the market. North America is expected to hold significant share in the market. The growth in the region is due to the well-developed healthcare and R&D sector that caters the requirement of new and advanced therapeutic vaccines.
Moreover, the study of the global therapeutic vaccine market report covers the analysis of various players operating in the market. Some of the key players covered in the report include Agenus Inc., GlaxoSmithKline plc, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sanofi SA, Eli Lilly and Co., and others. The market players are considerably contributing to the market growth by adopting various strategies including merger, and acquisition, collaborations with government, funding, and various advancements in the R&D to stay competitive in the market. For instance, in February 2019, Merck & Co. Inc. acquired Immune Design and its cancer vaccines platform in a deal of total $300 million.
Research Methodology
The market study of the global therapeutic vaccine market is incorporated by extensive primary and secondary research. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.
In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.
Secondary Sources Include:
- Financial reports of companies involved in the market.
- Whitepapers, research-papers, and news blogs.
- Company websites and their product catalog.
The report is intended for the pharmaceutical industry, drug manufacturers, vaccine manufacturers, hospitals & clinics, government organizations, regulatory bodies, and other market participants for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, market determinants, and future market growth. The report will serve as a source for a 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.
Market Segmentation:
1. Global Therapeutic Vaccine Market Research and Analysis by Product
2. Global Therapeutic Vaccine Market Research and Analysis by Technology
The Report Covers
- Comprehensive research methodology of the global therapeutic vaccine market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the global therapeutic vaccine market.
- Insights about market determinants which are stimulating the global therapeutic vaccine market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
Table of Contents
1. Report Summary
2. Market Overview and Insights
3. Competitive Landscape
4. Market Determinants
5. Market Segmentation
6. Regional Analysis
7. Company Profiles
Companies Mentioned
A selection of companies mentioned in this report includes:
- Affiris AG
- Agenus Inc.
- AstraZeneca PLC
- Bavarian Nordic A/S
- BioNTech SE
- CuraVac AG
- Eli Lilly and Co.
- Epivax Oncology Inc.
- Flow Pharma, Inc.
- GlaxoSmithKline plc
- Heat Biologics, Inc.
- ImmusanT, Inc.
- Inhibikase Therapeutics, Inc.
- Intervexion Therapeutics
- Mercia Pharma Inc.
- Merck & Co., Inc.
- Moderna, Inc.
- Novartis International AG
- Pfizer Inc.
- Sanofi SA
- Shanghai Fosun Pharma (Group) Co., Ltd.
- Transgene SA
- Vaccibody AS
- Vaxinano SE